Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sumatriptan PK/Safety via Sofusa vs Oral Imitrex in Healthy Subjects
NCT03229798Phase 1Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sumatriptan in migraine (6 arms), sponsored by Sorrento Therapeutics. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve at 48 hours. Started Jan 2018; status: completed.
02
Drugs
sumatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03229798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229798.